Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05296070 · ClinicalTrials.gov registry record · Phase 2
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
A Phase 2 study of Marginal Zone Lymphoma, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 4
- Study locations
NCT05296070 is a Phase 2 study of Marginal Zone Lymphoma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 50 participants, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (51% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05296070, a Phase 2 study of Marginal Zone Lymphoma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.
Conditions Studied
Interventions
- DRUG Loncastuximab tesirine 150 µg/Kg
- DRUG Loncastuximab tesirine 75µg/Kg
Study Locations (4)
California
- City of Hope National Medical Center - Duarte
Florida
- University of Miami - Miami
Georgia
- Emory University - Atlanta
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05296070
The ClinicalTrials.gov registry entry for NCT05296070 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (51% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Loncastuximab tesirine 150 µg/Kg is the first listed.
NCT05296070 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05296070 about?
NCT05296070 is a clinical study titled "Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma". The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on...
What is the current status of trial NCT05296070?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-06-21. Estimated completion is 2029-06-30.
What conditions does trial NCT05296070 study?
This clinical trial studies the following conditions: Marginal Zone Lymphoma.
What interventions are being tested in trial NCT05296070?
The interventions under investigation include: Loncastuximab tesirine 150 µg/Kg (DRUG), Loncastuximab tesirine 75µg/Kg (DRUG).
Who is sponsoring clinical trial NCT05296070?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05296070 being conducted?
This trial has 4 study locations across California, Florida, Georgia, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marginal Zone Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
-
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
RECRUITING · Phase 2
-
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.